- Home
- KNSA vs PTY Comparison
KNSA vs PTY Comparison
Compare KNSA & PTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KNSA | PTY |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.8B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | KNSA | PTY |
|---|---|---|
| Price | $43.54 | $12.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $51.33 | N/A |
| AVG Volume (30 Days) | 399.9K | ★ 550.4K |
| Earning Date | 10-28-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.65% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $597,973,000.00 | N/A |
| Revenue This Year | $62.63 | N/A |
| Revenue Next Year | $29.93 | N/A |
| P/E Ratio | $92.52 | ★ N/A |
| Revenue Growth | ★ 55.68 | N/A |
| 52 Week Low | $17.82 | $11.92 |
| 52 Week High | $43.73 | $14.88 |
Technical Indicators
Market Signals| Indicator | KNSA | PTY |
|---|---|---|
| Relative Strength Index (RSI) | 67.33 | 30.20 |
| Support Level | $40.77 | $12.85 |
| Resistance Level | $42.32 | $12.96 |
| Average True Range (ATR) | 1.45 | 0.08 |
| MACD | 0.12 | 0.00 |
| Stochastic Oscillator | 81.29 | 8.97 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About PTY Pimco Corporate & Income Opportunity Fund
PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.